Clinical trial
A Phase 2b Multicenter, Randomized, Open Label, Comparative Trial of MPC-4326 in Combination With a Two to Three Drug Optimized Background Regimen Versus an Optimized, Three to Four Drug Antiretroviral Regimen for the Treatment of Triple Class Antiretroviral Experienced, HIV-1 Infected Subjects Failing Current Therapy
NCT01026727 is registered in ClinicalTrials.gov with Myrexis Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b Multicenter, Randomized, Open Label, Comparative Trial of MPC-4326 in Combination With a Two to Three Drug Optimized Background Regimen Versus an Optimized, Three to Four Drug Antiretroviral Regimen for the Treatment of Triple Class Antiretroviral Experienced, HIV-1 Infected Subjects Failing Current Therapy
- Lead sponsor
- Myrexis Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 30, 2009
- Completion date
- June 30, 2010
- Enrollment
- 2 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.